- Gilead Sciences' (GILD) Q4 sales growth was helped by higher sales of GILD's newer HIV drugs: Stribild sales totaled $203M, up from $40M a year earlier, and Complera sales were $262M, more than double last year's level.
- Q4 Atripla sales +1.8% Y/Y to $933M, Truvada sales -2.2% Y/Y to $814M; antiviral product sales rose 22% to $2.64B, while cardiovascular product sales gained 25% to $268.5M.
- Sales of the much anticipated new hepatitis C treatment Sovaldi totaled $139M in the final weeks of 2013, after winning FDA approval in early December.
- Looking to 2014, GILD sees full-year sales of $11.3B-$11.5B, a view that excludes Sovaldi sales.
- Shares flat AH after rising 4% during regular trading.
From other sites
Video at CNBC.com (Aug 24, 2015)
Video at CNBC.com (Jul 29, 2015)
at CNBC.com (May 22, 2015)
Video at CNBC.com (Feb 3, 2015)
at CNBC.com (Feb 3, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs